A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing ...

Needham forecasts Biogen revenues to remain stable until 2025, rising ~3% by 2026. Biogen will face ongoing challenges as expectations for Leqembi need to adjusted to more realistic levels.

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Biogen Pharmachem Industries Ltd share price was up by 0.82% from the previous closing price of ₹1.22. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Looking to upgrade to a TV with a 120Hz refresh rate for next-gen gaming? These are the top options The best 120Hz 4K TVs are essential for gamers, movie lovers and sports fans. That's because the ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...